Imre (US) begins Prosorba trial for kidney transplantation:
This article was originally published in Clinica
Imre (US) has begun a clinical trial to evaluate the Prosorba column as a means to increase the number of patients eligible for kidney transplantation. The 15-patient study, to be carried out at the Cleveland Clinic, will determine if the Prosorba column reduces the level of sensitising antibodies which cause acute organ rejection. Imre estimates around a quarter of patients awaiting kidney transplantation are ineligible because they have developed alloantibodies to a variety of donor tissues.
You may also be interested in...
Approved in February as an on-demand remedy, Nurtec will be filed for migraine prevention after success in Phase III. It could be the first oral preventive therapy and first dual purpose migraine drug.
A protocol amendment is not needed to pause enrollment to decrease potential exposure to COVID-19, and virtual visits can be immediately implemented to ensure safety; experts say pandemic is forcing a rethinking in how companies carry out trials and in how regulators ensure patient safety and trial integrity.
South Korea’s Qurient achieves proof of concept in a Phase II study with its first-in-class antibiotic telacebec for tuberculosis and aims to file a US NDA for the orphan drug.